Trial Profile
Effectiveness of PEG-IFN alfa-2b + Ribavirin combination therapy in patients with chronic hepatitis C after partial splenic embolization(PSE) or splenectomy.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2012
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 08 Feb 2011 New trial record